OBJECTIVES: This study aimed to determine whether carbonic anhydrase-IX (CA-IX) was associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated withadjuvant pelvic radiotherapy with or without radiosensitizing chemotherapy. METHODS:CA-IX expression was detected using an immunohistochemistry assay and categorized as low when <or=80% of tumor cells exhibited CA-IX staining and high when >80% tumor cells display CA-IX staining. Associations between CA-IX expression and clinical characteristics, angiogenesis marker expression, and clinical outcome were evaluated. RESULTS:High CA-IX expression was observed in 35/166 (21.1%) of cases. CA-IX expression was not associated with age, race, stage, cell type, grade, positive margins, parametrial extensions, positive lymph nodes, or lymphovascular space invasion but was associated with tumor size categorized as <2 , 2-2.9 , or >or=3 cm (high expression: 4.7% vs. 23.2% vs. 32.5%, P=0.003) and cervical invasion confined to the inner two-thirds compared with the outer third of the cervix (high expression: 6.1% vs. 23.7%, P=0.028). CA-IX expression was not associated with immunohistochemical expression of p53, CD31, CD105, thrombospondin-1, or vascular endothelial growth factor-A. Women with high versus low CA-IX expression had similar PFS (P=0.053) and significantly worse OS (P=0.044). After adjusting for prognostic clinical covariates, high CA-IX expression was an independent prognostic factor for PFS (hazard ratio [HR]=2.12; 95% confidence interval [CI]=1.13-3.95; P=0.019) and OS (HR=2.41; 95% CI=1.24-4.68; P=0.009). CONCLUSIONS: Tumor hypoxia measured by immunohistochemical expression of CA-IX is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer.
RCT Entities:
OBJECTIVES: This study aimed to determine whether carbonic anhydrase-IX (CA-IX) was associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated with adjuvant pelvic radiotherapy with or without radiosensitizing chemotherapy. METHODS:CA-IX expression was detected using an immunohistochemistry assay and categorized as low when <or=80% of tumor cells exhibited CA-IX staining and high when >80% tumor cells display CA-IX staining. Associations between CA-IX expression and clinical characteristics, angiogenesis marker expression, and clinical outcome were evaluated. RESULTS: High CA-IX expression was observed in 35/166 (21.1%) of cases. CA-IX expression was not associated with age, race, stage, cell type, grade, positive margins, parametrial extensions, positive lymph nodes, or lymphovascular space invasion but was associated with tumor size categorized as <2 , 2-2.9 , or >or=3 cm (high expression: 4.7% vs. 23.2% vs. 32.5%, P=0.003) and cervical invasion confined to the inner two-thirds compared with the outer third of the cervix (high expression: 6.1% vs. 23.7%, P=0.028). CA-IX expression was not associated with immunohistochemical expression of p53, CD31, CD105, thrombospondin-1, or vascular endothelial growth factor-A. Women with high versus low CA-IX expression had similar PFS (P=0.053) and significantly worse OS (P=0.044). After adjusting for prognostic clinical covariates, high CA-IX expression was an independent prognostic factor for PFS (hazard ratio [HR]=2.12; 95% confidence interval [CI]=1.13-3.95; P=0.019) and OS (HR=2.41; 95% CI=1.24-4.68; P=0.009). CONCLUSIONS:Tumor hypoxia measured by immunohistochemical expression of CA-IX is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer.
Authors: James L Tatum; Gary J Kelloff; Robert J Gillies; Jeffrey M Arbeit; J Martin Brown; K S Clifford Chao; J Donald Chapman; William C Eckelman; Anthony W Fyles; Amato J Giaccia; Richard P Hill; Cameron J Koch; Murali Cherukuri Krishna; Kenneth A Krohn; Jason S Lewis; Ralph P Mason; Giovanni Melillo; Anwar R Padhani; Garth Powis; Joseph G Rajendran; Richard Reba; Simon P Robinson; Gregg L Semenza; Harold M Swartz; Peter Vaupel; David Yang; Barbara Croft; John Hoffman; Guoying Liu; Helen Stone; Daniel Sullivan Journal: Int J Radiat Biol Date: 2006-10 Impact factor: 2.694
Authors: S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307
Authors: S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: David Hedley; Melania Pintilie; Jennifer Woo; Andrew Morrison; Diana Birle; Anthony Fyles; Michael Milosevic; Richard Hill Journal: Clin Cancer Res Date: 2003-11-15 Impact factor: 12.531
Authors: Ann Driessen; Willy Landuyt; Sylvia Pastorekova; Johnny Moons; Laurence Goethals; Karin Haustermans; Philippe Nafteux; Freddy Penninckx; Karel Geboes; Toni Lerut; Nadine Ectors Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: J Saarnio; S Parkkila; A K Parkkila; K Haukipuro; S Pastoreková; J Pastorek; M I Kairaluoma; T J Karttunen Journal: Am J Pathol Date: 1998-07 Impact factor: 4.307
Authors: John P Kirkpatrick; Zahid N Rabbani; Rex C Bentley; Matt E Hardee; Seth Karol; Jeffrey Meyer; Egbert Oosterwijk; Laura Havrilesky; Angeles Alvarez Secord; Zeljko Vujaskovic; Mark W Dewhirst; Ellen L Jones Journal: Biomark Insights Date: 2008-02-01
Authors: Lidija Beketic-Oreskovic; Petar Ozretic; Zahid N Rabbani; Isabel L Jackson; Bozena Sarcevic; Sonja Levanat; Petra Maric; Ivan Babic; Zeljko Vujaskovic Journal: Pathol Oncol Res Date: 2011-01-20 Impact factor: 3.201
Authors: David J Stewart; Maria I Nunez; Carmen Behrens; Diane Liu; Yan Heather Lin; J Jack Lee; Jack Roth; John Heymach; Stephen G Swisher; Waun Ki Hong; Ignacio Ivan Wistuba Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Linn Woelber; Kerstin Kress; Jan F Kersten; Matthias Choschzick; Ergin Kilic; Uwe Herwig; Christoph Lindner; Joerg Schwarz; Fritz Jaenicke; Sven Mahner; Karin Milde-Langosch; Volkmar Mueller; Maike Ihnen Journal: BMC Cancer Date: 2011-01-11 Impact factor: 4.430
Authors: Volkmar Müller; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Erich Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Julia Zeitz; Klaus Pantel; Tanja Fehm Journal: Breast Cancer Res Date: 2011-07-11 Impact factor: 6.466